BUHLMANN Diagnostics

Executive Summary

BUHLMANN Diagnostics Corp, the U.S. commercial affiliate of Swiss-based BÜHLMANN Laboratories AG, specializes in developing and distributing specialized in vitro diagnostic (IVD) and research-use-only (RUO) assays. With nearly 50 years of heritage, the company focuses on gastroenterology (notably calprotectin testing for inflammatory bowel disease), autoimmunity, cellular allergy, neuroimmunology, and clinical chemistry. As a private entity headquartered in Portland, Oregon, BUHLMANN has established itself as a niche player in the diagnostics space, leveraging its parent company's expertise to provide high-quality assays for unmet medical needs. The company's core strength lies in its calprotectin tests, which are widely used for monitoring IBD, a growing market due to increasing disease prevalence and the shift toward non-invasive diagnostics. While detailed financials and recent milestones are not publicly available, BUHLMANN's long-standing presence and specialized portfolio position it for steady growth in the competitive diagnostics landscape. The company's U.S. focus enables it to capture a share of the large American healthcare market, and its parent's global reach provides manufacturing and R&D support.

Upcoming Catalysts (preview)

• Q2 2027FDA clearance for new calprotectin point-of-care test70% success
• Q1 2027Launch of expanded autoimmune assay panel60% success
• 2027Strategic distribution partnership in Asia50% success